Market Place
Sourcing Support
The unraveling of EQRx’s low-cost drug dream
05 Oct 2023 //
FIERCE BIOTECH
EQRx had limited buyer interest, tried acquiring other companies
04 Oct 2023 //
ENDPTS
Lynk’s JAK1 inhibitor improves severity, itching in eczema study
09 Aug 2023 //
FIERCE BIOTECH
Revolution Medicines, Inc. to Acquire EQRx, Inc.
01 Aug 2023 //
GLOBENEWSWIRE
EQRx sells itself to another Revolution Medicines, in all-stock deal
01 Aug 2023 //
ENDPTS
EQRx`s low cost drug dream ends in Revolution
01 Aug 2023 //
FIERCE BIOTECH
EQRx abandons low cost drug plan, cuts programs and staff
09 May 2023 //
FIERCE BIOTECH
EQRx to trim more than 40 staffers in restructuring maneuver
23 Feb 2023 //
ENDPTS
Impel, Cybin, EQRx trim head counts to prioritize easy wins
23 Feb 2023 //
FIERCE BIOTECH
Nearly a year after his SPAC combines with EQRx, Eli Casdin resigns from board
28 Nov 2022 //
ENDPTS
For its two medicines, EQRx abandons its bold strategy to lower drug prices
11 Nov 2022 //
STATNEWS
EQRx model in doubt as company concedes no path forward for sugemalimab in US
10 Nov 2022 //
FORBES
EQRx, in bid to compete, takes on AstraZeneca’s top seller in head-to-head trial
12 Aug 2022 //
BIOPHARMADIVE
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
11 Aug 2022 //
PRESS RELEASE
EQRx announces further results from phase 3 trial of sugemalimab
08 Aug 2022 //
PHARMATIMES
IDRx Launches with $122M Series A Financing to Treat CancerCombination Therapies
02 Aug 2022 //
BUSINESSWIRE
Aurigene inks drug discovery, development pact with US-based EQRx
04 Jul 2022 //
ECONOMIC TIMES
EQRx to Hold First Quarter 2022 Financial Results Conference Call
29 Apr 2022 //
PRESS RELEASE
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO
27 Apr 2022 //
PRESS RELEASE
Insilico Medicine Collaborates with EQRx for AI-driven Drug Discovery
24 Mar 2022 //
PRNEWSWIRE
EQRx adds armor to its discount checkpoint inhibitor submission
18 Jan 2022 //
ENDPTS
Merck leans into AI with $610 in biobucks for Absci
08 Jan 2022 //
FIERCEBIOTECH
EQRx, CM Life Sciences III Share Effectiveness of S-4 Registration Statement
02 Dec 2021 //
BUSINESSWIRE
EQRx, Abdul Latif Jameel Health Partner to Commercialize Lead Oncology Programs
22 Nov 2021 //
BUSINESSWIRE
EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership
18 Nov 2021 //
BUSINESSWIRE
EQRx and NHSE Sign MOU to Enter into England’s First Population
19 Oct 2021 //
BUSINESSWIRE
EQRx`s affordable drug drive leads to Absci discovery pact
07 Oct 2021 //
FIERCEBIOTECH
EQRx Appoints Kathy Giusti to Board of Directors
27 Sep 2021 //
BUSINESSWIRE
EQRx Announces Presentation of Ph3 Data Demonstrating Progression-Free Survival
17 Sep 2021 //
BUSINESSWIRE
EQRx, CStone unfurl full lung cancer data for PD-L1 drug
17 Sep 2021 //
ENDPTS
EQRx Presents PIII Data for Sugemalimab with Chemotherapy in Stage IV NSCLC
13 Sep 2021 //
BUSINESSWIRE
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
07 Sep 2021 //
BUSINESSWIRE
EQRx to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
07 Sep 2021 //
BUSINESSWIRE
EQRx Appoints Richard Buckley as Chief Corporate Affairs Officer
18 Aug 2021 //
BUSINESSWIRE
Drug pricing disruptor EQRx makes the big leagues with $1.8B SPAC deal
07 Aug 2021 //
FIERCEBIOTECH
EQRx to Accelerate Growth with $1.8 Billion Raise through Proposed Combination
06 Aug 2021 //
BUSINESSWIRE
EQRx and AbCellera Announce Collaboration
04 Aug 2021 //
BUSINESSWIRE
EQRx Announces Formation of Mission Advisory Board
20 Jul 2021 //
BUSINESSWIRE
Former Sanofi exec joins $750M-funded EQRx to lead drug creation
01 Jul 2021 //
FIERCEBIOTECH
EQRx and Exscientia Enter Strategic Drug Collaboration
26 Jun 2021 //
BUSINESSWIRE
No price competition in PD-(L)1? That might not last long as EQRx, CStone
29 May 2021 //
ENDPTS
